€ 38.7 Mio. German government funding for the clinical development of a Corona medication

by Jan | Jul 13, 2022 | 2021, 2022, News

CORAT Therapeutics GmbH receives € 38.7 Mio. funding for the clinical development of COR-101, a drug to treat hospitalized COVID-19 patients with moderate to severe symptomsClinical processing of COR-101 is financially securedPreparation for market entry in 2023...

For patients

by Jan | Feb 10, 2022

For patients Patienteninformation (Text/Deutsch) Was ist COR-101? COR 101 ist ein menschliches Eiweiß. Es ist genau so ein Antikörper, wie wir ihn selbst nach einer Impfung oder Infektion bilden. Tatsächlich wurde sein Bauplan aus einem gesundeten COVID-19 Patienten...

Products

by Jan | Oct 21, 2021

Products COR-101 The fully human antibody COR-101 is the lead product in our current pipeline. It binds to the viral RBD region and blocks the attachment of the virus to human cells. In pre-clinical studies, COR-101 decreased the SARS-CoV-2 virus load in the lung by...

Privacy-Statement

by Jan | Oct 20, 2021

Privacy Statement Effective Since: August, 13th 2021   We respect the privacy of our users and treat their personal data in the strictest confidentiality and in accordance with the legislation in force. The privacy statement is intended to inform you, in a...

Cookie policy

by Jan | Oct 20, 2021

Cookie policy Effective Since: June, 21st 2021   This policy relating to cookies (hereinafter, the »Cookie Policy«) describes the different types of cookies that we use on our website: www.corat-therapeutics.com (hereinafter, the »Website«) and the manner in...